Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Icosavax Appoints Thomas J. Russo Chief Financial Officer

Icosavax, Inc. today announced the appointment of Thomas J. Russo as Chief Financial Officer. Mr. Russo brings more than 25 years of diverse industry experience, including in finance and operations for public biotechnology companies, as a sell-side equity research analyst covering biotechnology, and in operations and vaccine manufacturing for a large pharma company.

“Tom is a great fit for Icosavax. He has extensive expertise across biotech finance, operations, and the investment community, combined with relevant experience in vaccine manufacturing and a deep drive to advance innovative medical products to address infectious diseases,” said Adam Simpson, Chief Executive Officer of Icosavax. “He makes a great addition to our team, as we advance our vaccine candidates to address significant unmet medical needs in protecting at-risk populations from life-threatening respiratory viruses, including RSV, hPMV, and SARS-CoV-2.”

“I am thrilled to be joining Icosavax at such an exciting time for the company, as the opportunity for next generation vaccine technologies has never been clearer,” said Mr. Russo. “From my earliest career experiences, I have been motivated by the impact that vaccine innovation can have on the world’s health. I’m impressed by the company’s computationally-designed virus-like particle platform technology, because I believe it has the potential to generate best-in-class products, and I look forward to working with the highly-experienced team at Icosavax to advance it.”

Mr. Russo joins Icosavax from Assembly Biosciences, Inc., a clinical-stage, public biotechnology company, where he was Chief Financial Officer and contributed to more than $220 million of gross proceeds raised through the capital markets and non-dilutive sources of financing. Previously, he spent seven years across finance and commercial operations roles at Gilead Sciences, Inc., including serving as Vice President, Head of Commercial Finance. In that role, he supported a $20-30 billion revenue business and multibillion-dollar budget across North America, Europe, Asia, and emerging markets. Prior to Gilead, Mr. Russo was Equity Research Senior Analyst covering biotechnology for investment bank, Robert W. Baird & Co., Incorporated, where he advised institutional investors and received WSJ Best on the Street recognition. Earlier in his career he was at Merck & Co., Inc., in roles of increasing responsibility within the manufacturing division and with particular focus on vaccines. Mr. Russo received a B.S. in biological sciences from the University of Notre Dame and an MBA from the University of Chicago Booth School of Business. He is also a CFA charterholder.

About Icosavax

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax exclusively licensed the VLP technology for use in several vaccine fields, including RSV and hMPV, and four other infectious diseases, from the University of Washington. For SARS-CoV-2, Icosavax has a non-exclusive, worldwide (excluding South Korea) license, along with an option to convert to exclusive rights in North America and Europe from the University of Washington. Icosavax is located in Seattle. For more info, visit www.icosavax.com.

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.